{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:13:13Z","timestamp":1792843993355,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jhep.2023.02.004","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:24:48Z","timestamp":1676665488000},"page":"914-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Evaluation of PXL065 \u2013 deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)"],"prefix":"10.1016","volume":"78","author":[{"given":"Stephen A.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Thang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bolze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0354-177X","authenticated-orcid":false,"given":"Sheila","family":"Dewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-9518","authenticated-orcid":false,"given":"Sophie","family":"Hallakou-Bozec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-8075","authenticated-orcid":false,"given":"Julie","family":"Dubourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bedossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-0111","authenticated-orcid":false,"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Grouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-4678","authenticated-orcid":false,"given":"David E.","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Fouqueray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.02.004_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the middle east and north Africa: data from global burden of disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib3","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.02.004_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.02.004_bib5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib6","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.24042","article-title":"Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues","volume":"52","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.02.004_bib8","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects\u00a0with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.02.004_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A\u00a0pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.02.004_bib11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.02.004_bib12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.02.004_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: real life differs from published guidelines","volume":"9","author":"Rinella","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2023.02.004_bib16","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1073\/pnas.1303360110","article-title":"Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier","volume":"110","author":"Divakaruni","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2023.02.004_bib17","doi-asserted-by":"crossref","first-page":"24667","DOI":"10.1074\/jbc.M010793200","article-title":"Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones","volume":"276","author":"Kim","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.02.004_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jhep.2023.02.004_bib19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.29025","article-title":"Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"65","author":"McCommis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib20","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.molmet.2017.09.002","article-title":"The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity","volume":"6","author":"Rauckhorst","year":"2017","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.02.004_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molmet.2018.01.012","article-title":"A\u00a0role for long-chain acyl-CoA synthetase-4 (ACSL4) in diet-induced phospholipid remodeling and obesity-associated adipocyte dysfunction","volume":"9","author":"Killion","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.02.004_bib22","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2337\/db07-0156","article-title":"Genes involved in fatty acid partitioning and binding, lipolysis, monocyte\/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects","volume":"56","author":"Westerbacka","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.02.004_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41419-019-1678-y","article-title":"Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis","volume":"10","author":"Tsurusaki","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhep.2023.02.004_bib24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/hep4.1723","article-title":"Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is responsible for Pioglitazone efficacy in NASH yet exhibits little to no PPARgamma activity","volume":"5","author":"Jacques","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.02.004_bib25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jimd.12510","article-title":"Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy","volume":"45","author":"Monternier","year":"2022","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jhep.2023.02.004_bib26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib27","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib28","article-title":"Noninvasive tests (NITs) in the management of nonalcoholic steatohepatitis (NASH)","volume":"16","author":"Harrison","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/hep4.1680","article-title":"Relationship of ELF and PIIINP with liver histology and response to vitamin E or Pioglitazone in the PIVENS trial","volume":"5","author":"Gawrieh","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.02.004_bib30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib31","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1210\/jc.2017-00047","article-title":"How to measure adipose tissue insulin sensitivity","volume":"102","author":"Sondergaard","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.02.004_bib32","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0026-895X(25)09536-7","article-title":"Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells","volume":"50","author":"Gimble","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2023.02.004_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term Pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2023.02.004_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2019.09.018","article-title":"Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis","volume":"72","author":"Bril","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.02.004_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.02.004_bib37","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.02.004_bib38","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.02.004_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2017.12.001","article-title":"A\u00a0critical review of endpoints for non-cirrhotic NASH therapeutic trials","volume":"68","author":"Ratziu","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib40","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib41","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis","volume":"23","author":"Panunzi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.02.004_bib42","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.28960","article-title":"Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges","volume":"65","author":"Musso","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.02.004_bib44","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","article-title":"Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in\u00a0vivo and in\u00a0vitro","volume":"122","author":"Galli","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.02.004_bib45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep.510310117","article-title":"Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells","volume":"31","author":"Galli","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/bbrc.2002.6385","article-title":"Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride","volume":"291","author":"Kon","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2023.02.004_bib47","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2006.05.005","article-title":"Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement","volume":"4","author":"Lutchman","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib48","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2036.2010.04405.x","article-title":"Pioglitazone in the treatment of NASH: the role of adiponectin","volume":"32","author":"Gastaldelli","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.02.004_bib49","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/endo.143.3.8662","article-title":"Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization","volume":"143","author":"Combs","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jhep.2023.02.004_bib50","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.02.004_bib51","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.02.004_bib52","unstructured":"European, Medicines, Agency. Actos product information, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/actos-epar-product-information_en.pdf."},{"key":"10.1016\/j.jhep.2023.02.004_bib53","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.02.004_bib54","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm1672","article-title":"PPAR-gamma regulates osteoclastogenesis in mice","volume":"13","author":"Wan","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.02.004_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jbmr.2364","article-title":"An insulin-sensitizing thiazolidinedione, which minimally activates PPARgamma, does not cause bone loss","volume":"30","author":"Fukunaga","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jhep.2023.02.004_bib56","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hep.32148","article-title":"Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice","volume":"75","author":"Duan","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib58","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajpath.2019.09.011","article-title":"Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice","volume":"190","author":"Qi","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2023.02.004_bib59","doi-asserted-by":"crossref","first-page":"G117","DOI":"10.1152\/ajpgi.00246.2015","article-title":"Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice","volume":"310","author":"Handa","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2023.02.004_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194968","article-title":"Programmed cell-death by ferroptosis: antioxidants as mitigators","volume":"20","author":"Kajarabille","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.02.004_bib61","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1096\/fj.10-173716","article-title":"Role for PPAR\u03b3 in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts","volume":"25","author":"Mor\u00e1n-Salvador","year":"2011","journal-title":"Faseb j"},{"key":"10.1016\/j.jhep.2023.02.004_bib62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement\u00a0with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.02.004_bib63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.02.004_bib64","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J\u00a0Biol Chem"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:00Z","timestamp":1759175280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0168827823000910"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.02.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of PXL065 \u2013 deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}